Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPACET 100 vs ANEXSIA 5/325
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.
Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.
Management of mild to moderate pain,Fever reduction,Off-label: Treatment of osteoarthritis pain (as acetaminophen)
Management of moderate to moderately severe pain where an opioid analgesic is appropriate
1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.
1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
The terminal elimination half-life of acetaminophen after propacetamol administration is approximately 2–3 hours in adults with normal hepatic function. This half-life may be prolonged in patients with hepatic impairment or overdose.
Oxycodone: terminal half-life 3.2-4.3 hours (immediate-release); prolonged in hepatic impairment. Acetaminophen: terminal half-life 2-3 hours (therapeutic doses); prolonged in hepatic impairment or overdose.
Rapidly hydrolyzed by plasma esterases to acetaminophen; acetaminophen is primarily metabolized by glucuronidation and sulfation, with a minor pathway via CYP2E1 to the toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI).
Hydrocodone: primarily hepatic via CYP3A4 and CYP2D6 to active metabolites (hydromorphone). Acetaminophen: hepatic metabolism via conjugation (glucuronidation, sulfation) and CYP2E1-mediated oxidation to toxic NAPQI.
Propacet 100 (propacetamol) is a prodrug of acetaminophen. Renal elimination accounts for >90% of the administered dose, with approximately 85% as acetaminophen glucuronide and sulfate conjugates, and about 5% as unchanged acetaminophen. Biliary/fecal elimination is minimal (<5%).
Oxycodone: renal excretion of metabolites (conjugated and unconjugated) and parent drug; ~10% excreted unchanged. Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates); ~2-4% excreted unchanged.
Acetaminophen is minimally bound to plasma proteins, with protein binding of approximately 10–25% at therapeutic concentrations. It binds primarily to albumin.
Oxycodone: 38-45% bound to albumin and alpha-1-acid glycoprotein. Acetaminophen: 10-25% bound to albumin at therapeutic concentrations.
The volume of distribution (Vd) of acetaminophen is approximately 0.9–1.0 L/kg, indicating distribution into total body water. This reflects its hydrophilic nature and widespread tissue penetration.
Oxycodone: Vd 2.0-3.0 L/kg; distributes extensively into tissues. Acetaminophen: Vd 0.8-1.0 L/kg; relatively uniform distribution.
Propacetamol is administered intravenously; thus, bioavailability is 100%. After hydrolysis to acetaminophen, the bioavailability of active acetaminophen is essentially complete.
Oxycodone: oral bioavailability 60-87% (immediate-release). Acetaminophen: oral bioavailability 88-98% (therapeutic doses).
GFR 30-50 m L/min: extend interval to every 8 hours; GFR <30 m L/min: extend interval to every 12 hours; hemodialysis: dose post-dialysis.
GFR 30-50 m L/min: use with caution, increase dosing interval to every 6 hours; GFR <30 m L/min: avoid use due to hydrocodeone accumulation.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use alternative analgesic.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: contraindicated.
10-15 mg/kg/dose propacetamol equivalent every 6 hours; maximum 60 mg/kg/day; do not exceed adult dose.
Not recommended for children under 18 years due to risk of respiratory depression.
Initiate at lower end of dosing range (100 mg every 6 hours); maximum 800 mg/day; monitor renal and hepatic function.
Start with lowest dose (1 tablet every 6 hours), monitor renal and hepatic function, and avoid in frail elderly due to increased fall and cognitive impairment risk.
No FDA black box warning exists for propacetamol specifically; however, acetaminophen (active metabolite) carries a risk of severe liver injury in cases of overdose, particularly with chronic alcohol use or hepatic impairment.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; and hepatotoxicity from acetaminophen overdose.
Hepatotoxicity risk with overdose or chronic alcohol use; severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) reported rarely; use with caution in hepatic impairment, alcohol use disorder, or malnutrition.
Risk of opioid addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or other CNS depressants; hepatotoxicity; adrenal insufficiency; severe hypotension; gastrointestinal obstruction; seizure; and serotonin syndrome.
History of hypersensitivity to acetaminophen or propacetamol; severe hepatic impairment; use of MAOIs (potential interaction).
Hypersensitivity to hydrocodone or acetaminophen; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; severe hepatic impairment; and concurrent use of MAOIs within 14 days.
No specific food interactions; however, maintain adequate caloric intake to support glutathione synthesis. Avoid alcohol as it may increase hepatotoxicity risk.
Avoid alcohol. Grapefruit juice may enhance side effects; limit intake. Take with food to reduce gastrointestinal discomfort.
Propacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Second and third trimesters: No known fetal toxicity at therapeutic doses; overdose may cause hepatic necrosis in mother and potentially fetus.
First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal renal toxicity, oligohydramnios, and premature closure of ductus arteriosus. Use only if clearly needed.
Paracetamol is excreted into breast milk in trace amounts; milk-to-plasma ratio (M/P) is approximately 0.1-0.2. At maternal therapeutic doses, infant exposure is less than 2% of maternal weight-adjusted dose, considered compatible with breastfeeding.
Paracetamol and hydrocodone are excreted in breast milk. M/P ratio: paracetamol ~1.0, hydrocodone ~1.0-2.0. Use with caution; monitor infant for drowsiness and respiratory depression. Consider risk of infant sedation with long-term use.
Pharmacokinetic changes in pregnancy include increased clearance and volume of distribution of paracetamol, but no dose adjustment is required for Propacet 100; standard adult doses (500-1000 mg every 4-6 hours, max 4 g/day) are safe and effective.
Increased clearance in pregnancy may require dose adjustment. Monitor for pain control and adverse effects; no fixed dose change recommended. Consider lower starting dose due to potential fetal risks. Avoid chronic use; taper if possible.
Propacet 100 (propacetamol, a prodrug of acetaminophen) is administered intravenously; ensure patency of IV line to prevent extravasation, which can cause injection site reactions. Contraindicated in severe hepatic impairment (Child-Pugh C) and in patients with glutathione depletion (e.g., malnutrition, sepsis). Monitor liver function tests during prolonged use. Use with caution in patients with asthma, as sulfite in formulation may trigger bronchospasm.
ANEXSIA 5/325 contains hydrocodone 5 mg and acetaminophen 325 mg. Maximum acetaminophen dose from all sources should not exceed 4 g/day in adults; avoid in severe hepatic impairment. Hydrocodone is a Schedule II controlled substance with abuse potential; monitor for respiratory depression, especially in opioid-naive patients. Use with caution in patients with COPD, sleep apnea, or increased intracranial pressure. Consider naloxone co-prescription for high-risk patients. For acute pain, limit duration to 3-7 days.
Propacet 100 is given intravenously for pain or fever; you must receive it in a healthcare setting.,Report any signs of allergic reaction such as rash, itching, swelling, or trouble breathing immediately.,This medication is a prodrug of acetaminophen; do not take additional acetaminophen-containing products while on this therapy.,Avoid alcohol during treatment to reduce risk of liver damage.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not consume alcohol or other sedatives (e.g., benzodiazepines) while taking this medication.,Avoid other products containing acetaminophen (e.g., Tylenol, cold remedies) to prevent liver damage.,This medication may cause drowsiness or dizziness; do not drive or operate machinery until you know how it affects you.,Store securely out of reach of others; dispose of unused medication via drug take-back programs.,Seek emergency help if you have trouble breathing, severe drowsiness, or signs of allergic reaction.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPACET 100 vs ANEXSIA 5/325, answered by our medical review team.
PROPACET 100 is a Opioid analgesic combination that works by Propacet 100 is a prodrug of acetaminophen; it is hydrolyzed to acetaminophen, which inhibits cyclooxygenase (COX) and modulates the endogenous cannabinoid system, leading to analgesic and antipyretic effects.. ANEXSIA 5/325 is a Opioid Analgesic Combination that works by Hydrocodone is a semi-synthetic opioid agonist that binds to mu-opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception. Acetaminophen is a para-aminophenol derivative with analgesic and antipyretic effects, primarily through central COX-2 inhibition and activation of descending serotonergic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPACET 100 and ANEXSIA 5/325 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPACET 100 is: 1-2 tablets (100-200 mg propacetamol) orally every 4-6 hours; maximum 8 tablets (800 mg) per day.. The standard adult dose of ANEXSIA 5/325 is: 1-2 tablets orally every 4-6 hours as needed for pain; maximum 8 tablets per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPACET 100 and ANEXSIA 5/325 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPACET 100 is classified as Category C. Propacet 100 (propacetamol) is a prodrug of paracetamol (acetaminophen). First trimester: Limited human data, no increased risk of major malformations in large cohort studies. Seco. ANEXSIA 5/325 is classified as Category C. First trimester: Associated with increased risk of neural tube defects and cardiovascular malformations; avoid use. Second and third trimesters: Chronic exposure may cause fetal re. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.